<DOC>
	<DOC>NCT00750880</DOC>
	<brief_summary>This open-label, single arm study will investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biologic disease modifying antirheumatic drugs (DMARDs), in patients with severe active RA. Patients will receive tocilizumab 8mg/kg iv as a 60 minute infusion every 4 weeks for a total of 6 infusions. The anticipated time on study treatment is 3-12 months, and the target sample size is &gt;500 individuals.</brief_summary>
	<brief_title>An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>male and nonpregnant or nursing female patients &gt;=18 years of age; body weight &lt;=150kg; moderate to severe active RA (DAS28 &gt;=3.2) of &gt;=6 months duration; on &gt;=1 nonbiologic DMARDs at a stable dose for a period of &gt;= 8 weeks prior to start of treatment; inadequate clinical response to a stable dose of nonbiologic DMARD or antiTNF therapy; if receiving oral corticosteroids, the dose must have been stable for at least 25 of 28 days prior to start of treatment. major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment; rheumatic autoimmune disease other than RA; prior history of, or current inflammatory joint disease other than RA; functional class IV as defined by the ACR Classification of Functional Status in RA.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>